Shares of Cambridge-based Mersana Therapeutics Inc. plunged Monday despite announcing that the FDA would allow it to fully restart a cancer drug trial that was paused in July after one patient died.
www.bizjournals.com/...ana-cancer-drug.html
globenewswire.com/ne...ld-for-XMT-1522.html
www.bizjournals.com/...ana-cancer-drug.html
globenewswire.com/ne...ld-for-XMT-1522.html